Israel Cancer Research Fund (ICRF) Career Development Awards (CDAs) are designed to enhance the research capabilities of young Israeli scientists in the formative phase of their careers who have demonstrated outstanding potential for contribution to cancer research as independent investigators. CDAs are available to investigators with clear research potential who will benefit by additional mentored experience in a scientific environment that is conducive to the development of an independent research career. A candidate must have a doctoral degree and at least three (3) years of postdoctoral fellowship or equivalent experience, hold an independent junior position at an Israeli institution, and be within five (5) years of initial appointment to that position at the start date of requested funding.
Duration and Amount of the Grant
The duration of a CDA is three (3) years, at a level of $45,000 per year, as determined by the ICRF International Board and availability of funds. Funding for the second and third years is contingent upon progress in the preceding funding period, as documented in a progress report due annually on June 30. CDA grants are not renewable.
ICRF supports all areas of cancer research (basic → translational → clinical), but successful proposals have a clear cancer-specific rationale, such as:
Cancer genetics and epigenetics
Tumor immunology & immunotherapy
Tumor microenvironment
Drug discovery & targeted therapy
Early detection and biomarkers
Cancer metabolism
Computational/AI cancer biology
Tumor heterogeneity & resistance
Metastasis mechanisms
Predictor: Your proposal must explicitly advance understanding of cancer mechanisms, detection, or treatment.
ICRF has multiple grant types, each with unique expectations:
🔹 ICRF Research Career Development Award (RCDA)
For early-career faculty in Israel (or Israeli scientists abroad starting jobs in Israel).
Requires strong mentorship, independence plan, and institutional commitment.
🔹 ICRF Project Grants (core mechanism)
1–3 year research projects.
Requires strong preliminary data + feasibility.
🔹 ICRF Acceleration Grants
High-risk, high-impact, innovative work with transformative potential.
🔹 ICRF–AACR Partner Awards / Thematic Calls
Highly specific cancer areas, often translational.
🔹 ICRF–U.S. Partnerships (e.g., ICRF–Chicago, ICRF–Toronto)
May include priority disease areas.
Predictor: Match career stage, institution, and project type to the correct grant.
Even for “acceleration” or early-career awards, competitive proposals include:
Pilot data supporting feasibility
Validation of methods or models
Early signals supporting the hypothesis
Demonstration that required datasets/materials are available
Predictor: ICRF rarely funds projects that lack preliminary evidence.
ICRF reviewers favor projects that:
Push boundaries (not incremental)
Introduce new tools, paradigms, or therapeutic strategies
Offer clear translational or mechanistic advances
Could lead to major discoveries in cancer biology or treatment
Address unmet medical needs or hard-to-treat cancers
Predictor: Innovation + potential to meaningfully impact cancer care or science.
Funded investigators typically demonstrate:
High-quality recent publications
Productivity in the proposed field
Ability to execute similar research
Successful mentorship and collaborations
Predictor: A strong publication record closely aligned with the proposed topic.
ICRF funds research conducted in Israel only (with rare joint exceptions). Strong proposals show:
Access to relevant research infrastructure (omics, imaging, bioinformatics, PDXs, patient samples)
Strong departmental and institutional support
Commitment of lab space, resources, core facilities
Predictor: Being at a leading Israeli research center with appropriate facilities strongly boosts competitiveness.
Strong ICRF proposals include:
2–3 focused Aims
Clear hypotheses, endpoints, and methods
Feasible 1–3 year execution timeline
Go/no-go milestones
Risk mitigation strategies
Predictor: Realistic, tightly structured projects score much higher.
ICRF values Israeli scientific collaboration—especially cross-institutional or cross-disciplinary partnerships.
Strong proposals often include:
Joint Israeli–international collaborations
Multi-PI synergy (e.g., computational + wet-lab + clinical)
Co-mentorship for early-career applicants
Predictor: Collaborative value improves competitiveness.
Successful ICRF grant applications are:
Very clearly written
Well organized (NIH-like structure)
Supported by strong figures for preliminary data
Persuasive in rationale and impact
Predictor: Clarity of the proposal has a major effect on reviewer enthusiasm.
ICRF has a dual mission:
Advance cancer research
Strengthen Israeli scientific excellence
Applications score higher if they demonstrate:
Training and building capacity in Israel
Contribution to Israeli research leadership
Potential to attract future external funding (NIH, ERC, etc.)
Predictor: Explicitly showing how your work strengthens Israel’s cancer research ecosystem.
| Predictor | Why It Matters |
|---|---|
| Cancer-specific focus | Core eligibility |
| Correct mechanism alignment | Ensures proper scope & expectations |
| Strong preliminary data | Demonstrates feasibility |
| Innovation + high impact | Central ICRF priority |
| Strong publication track record | Predictor of successful outcomes |
| Strong Israeli institutional support | Required for infrastructure and execution |
| Collaborative value | Enhances impact |
| Feasible aims & timeline | Supports high reviewer confidence |
| Clear, persuasive writing | Improves scores |
| Contribution to Israeli cancer research | Aligns with ICRF mission |
CDAs are intended for highly-qualified, early-career investigators with strong track records and a commitment to an independent career in cancer research. Individuals who have attained senior faculty or equivalent status are considered to have achieved the objective of this program and to be ineligible.
CDA funds cannot be budgeted or used for salary support of the PI, nor do they provide support to the institution or substitute for institutional support of an investigator.
Eligible Countries:
Sponsor Institute/Organizations: Israel Cancer Research Fund
Sponsor Type: Corporate/Non-Profit
Address: 52 Vanderbilt Avenue Suite 1410 New York, NY 10017-3835
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Jan 06, 2026
Jan 06, 2026
$45,000
Affiliation: Israel Cancer Research Fund
Address: 52 Vanderbilt Avenue Suite 1410 New York, NY 10017-3835
Website URL: https://www.icrfonline.org/grants/#cda
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.